Table of Contents

1 Study Coverage

• 1.1 Rifampicin Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Rifampicin Market Size Growth Rate by Product
  • 1.4.2 Oral
  • 1.4.3 Intravenous Injection
• 1.5 Market by End User
  • 1.5.1 Global Rifampicin Market Size Growth Rate by End User
  • 1.5.2 Tuberculosis
  • 1.5.3 Leprosy
  • 1.5.4 Legionnaire's Disease
  • 1.5.5 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Rifampicin Market Size
  • 2.1.1 Global Rifampicin Revenue 2014-2025
  • 2.1.2 Global Rifampicin Sales 2014-2025
• 2.2 Rifampicin Growth Rate by Regions
  • 2.2.1 Global Rifampicin Sales by Regions
  • 2.2.2 Global Rifampicin Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Rifampicin Sales by Manufacturers
  • 3.1.1 Rifampicin Sales by Manufacturers
  • 3.1.2 Rifampicin Sales Market Share by Manufacturers
  • 3.1.3 Global Rifampicin Market Concentration Ratio (CR5 and HHI)
• 3.2 Rifampicin Revenue by Manufacturers
  • 3.2.1 Rifampicin Revenue by Manufacturers (2014-2019)
  • 3.2.2 Rifampicin Revenue Share by Manufacturers (2014-2019)
• 3.3 Rifampicin Price by Manufacturers
• 3.4 Rifampicin Manufacturing Base Distribution, Product Types
  • 3.4.1 Rifampicin Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Rifampicin Product Type
  • 3.4.3 Date of International Manufacturers Enter into Rifampicin Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Rifampicin Sales by Product
• 4.2 Global Rifampicin Revenue by Product
• 4.3 Rifampicin Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Rifampicin Breakdown Data by End User

6 North America

• 6.1 North America Rifampicin by Countries
  • 6.1.1 North America Rifampicin Sales by Countries
  • 6.1.2 North America Rifampicin Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Rifampicin by Product
• 6.3 North America Rifampicin by End User

7 Europe

• 7.1 Europe Rifampicin by Countries
  • 7.1.1 Europe Rifampicin Sales by Countries
  • 7.1.2 Europe Rifampicin Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Rifampicin by Product
• 7.3 Europe Rifampicin by End User

8 Asia Pacific

• 8.1 Asia Pacific Rifampicin by Countries
  • 8.1.1 Asia Pacific Rifampicin Sales by Countries
  • 8.1.2 Asia Pacific Rifampicin Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Rifampicin by Product
• 8.3 Asia Pacific Rifampicin by End User

9 Central & South America

• 9.1 Central & South America Rifampicin by Countries
  • 9.1.1 Central & South America Rifampicin Sales by Countries
  • 9.1.2 Central & South America Rifampicin Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Rifampicin by Product
• 9.3 Central & South America Rifampicin by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Rifampicin by Countries
  • 10.1.1 Middle East and Africa Rifampicin Sales by Countries
  • 10.1.2 Middle East and Africa Rifampicin Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Rifampicin by Product
• 10.3 Middle East and Africa Rifampicin by End User

11 Company Profiles

• 11.1 Sanofi
  • 11.1.1 Sanofi Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Sanofi Rifampicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Sanofi Rifampicin Products Offered
  • 11.1.5 Sanofi Recent Development
• 11.2 Wellona Pharma
  • 11.2.1 Wellona Pharma Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Wellona Pharma Rifampicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Wellona Pharma Rifampicin Products Offered
  • 11.2.5 Wellona Pharma Recent Development
• 11.3 AVANSCURE LIFESCIENCES
  • 11.3.1 AVANSCURE LIFESCIENCES Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 AVANSCURE LIFESCIENCES Rifampicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 AVANSCURE LIFESCIENCES Rifampicin Products Offered
  • 11.3.5 AVANSCURE LIFESCIENCES Recent Development
• 11.4 Hebei Xingang Pharmaceutical
  • 11.4.1 Hebei Xingang Pharmaceutical Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Hebei Xingang Pharmaceutical Rifampicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Hebei Xingang Pharmaceutical Rifampicin Products Offered
  • 11.4.5 Hebei Xingang Pharmaceutical Recent Development
• 11.5 Mercator Pharmaceutical Solutions
  • 11.5.1 Mercator Pharmaceutical Solutions Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Mercator Pharmaceutical Solutions Rifampicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Mercator Pharmaceutical Solutions Rifampicin Products Offered
  • 11.5.5 Mercator Pharmaceutical Solutions Recent Development
• 11.6 ASIAN PHARMACY
  • 11.6.1 ASIAN PHARMACY Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 ASIAN PHARMACY Rifampicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 ASIAN PHARMACY Rifampicin Products Offered
  • 11.6.5 ASIAN PHARMACY Recent Development
• 11.7 A. S. JOSHI & COMPANY
  • 11.7.1 A. S. JOSHI & COMPANY Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 A. S. JOSHI & COMPANY Rifampicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 A. S. JOSHI & COMPANY Rifampicin Products Offered
  • 11.7.5 A. S. JOSHI & COMPANY Recent Development

12 Future Forecast

• 12.1 Rifampicin Market Forecast by Regions
  • 12.1.1 Global Rifampicin Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Rifampicin Revenue Forecast by Regions 2019-2025
• 12.2 Rifampicin Market Forecast by Product
  • 12.2.1 Global Rifampicin Sales Forecast by Product 2019-2025
  • 12.2.2 Global Rifampicin Revenue Forecast by Product 2019-2025
• 12.3 Rifampicin Market Forecast by End User
• 12.4 North America Rifampicin Forecast
• 12.5 Europe Rifampicin Forecast
• 12.6 Asia Pacific Rifampicin Forecast
• 12.7 Central & South America Rifampicin Forecast
• 12.8 Middle East and Africa Rifampicin Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Rifampicin Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Rifampicin, also known as rifampin, is an antibiotic used to treat several types of bacterial infections, including tuberculosis, mycobacterium avium complex, leprosy, and Legionnaire's disease. Common side effects include nausea, vomiting, diarrhea, and loss of appetite.
The global Rifampicin market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Rifampicin market based on company, product type, end user and key regions.

This report studies the global market size of Rifampicin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Rifampicin in these regions.
This research report categorizes the global Rifampicin market by top players/brands, region, type and end user. This report also studies the global Rifampicin market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sanofi
Wellona Pharma
AVANSCURE LIFESCIENCES
Hebei Xingang Pharmaceutical
Mercator Pharmaceutical Solutions
ASIAN PHARMACY
A. S. JOSHI & COMPANY

Market size by Product
Oral
Intravenous Injection
Market size by End User
Tuberculosis
Leprosy
Legionnaire's Disease
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Rifampicin market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Rifampicin market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Rifampicin companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Rifampicin submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Rifampicin are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Rifampicin market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.